Bristol Myers Squibb has presented groundbreaking 10-year follow-up data from its CheckMate -067 trial, which highlights the long-term survival benefits of the Opdivo (nivolumab) and Yervoy (ipilimumab) combination in treating advanced melanoma. These results, revealed at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, mark the longest reported median overall survival […]
Scorpion Therapeutics, Inc. has presented initial clinical data from its Phase 1/2 trial of STX-478, a mutant-selective PI3Kα inhibitor for the treatment of advanced solid tumors, at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain. The data reveals that STX-478 demonstrated a potentially best-in-class inhibition profile, with significant anti-tumor activity across […]
Merck & Co., Inc. (known as MSD outside the United States and Canada) and Eisai Co., Ltd. have announced encouraging results from the first interim analysis of the Phase 3 LEAP-012 trial evaluating the efficacy of KEYTRUDA (pembrolizumab), an anti-PD-1 therapy by Merck, combined with LENVIMA (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor […]
